SCHEMBL16006047

SCHEMBL16006047

COc1cc(NC(=O)[C@@H](CCc2ccccc2)NC(=O)OC(C)(C)C)ccc1Br

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 5/20 0.57
▸ CTSS P25774 5/20 0.57
▸ HDAC4 P56524 3/20 0.51
▸ HDAC1 Q13547 3/20 0.51
▸ HDAC8 Q9BY41 2/20 0.49
▸ HDAC3 O15379 1/20 0.49
▸ HDAC7 Q8WUI4 1/20 0.49
▸ HDAC2 Q92769 1/20 0.49
▸ HDAC10 Q969S8 1/20 0.49
▸ HDAC11 Q96DB2 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.49
▸ HDAC9 Q9UKV0 1/20 0.49
▸ HDAC5 Q9UQL6 1/20 0.49
▸ ROCK2 O75116 2/20 0.46
▸ ROCK1 Q13464 2/20 0.46
▸ SCN9A Q15858 1/20 0.46
▸ SIRT5 Q9NXA8 1/20 0.45
▸ AAK1 Q2M2I8 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ CTSB P07858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15994890 0.88 ROCK2 (0.50) HDAC4HDAC1HDAC8HDAC3HDAC7
SCHEMBL8695864 0.84 CTSK (0.63) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL17783050 0.83 AAK1 (0.58) CTSKCTSSAAK1CTSBCTSL
SCHEMBL17783051 0.83 AAK1 (0.58) CTSKCTSSAAK1CTSBCTSL
SCHEMBL7722248 0.83 CTSK (0.62) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL17407611 0.83 CTSK (0.49) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL17394739 0.81 ROCK2 (0.50) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL16006040 0.81 ROCK2 (0.49) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL7728624 0.81 CTSK (0.64) CTSKCTSSHDAC4HDAC1HDAC8
SCHEMBL7726821 0.80 CTSK (0.58) CTSKCTSSHDAC4HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828345-B2 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-11-28 — — US disclosed
US-9828345-B2 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-11-28 — — US disclosed
US-20160002172-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2016-01-07 — — US disclosed
US-20160002172-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2016-01-07 — — US disclosed
WO-2014134391-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002172-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS ROCK1, ROCK2, MYLK CTSK 2631/4885CTSS 3425/4885HDAC4 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback